-
Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis
•
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced its subsidiary GenScipt Biotech Corp. receiving approval to initiate a clinical study for its GenSci120 in rheumatoid arthritis (RA) in the United States. This marks a significant step forward in the development of this innovative biologic product for…
-
Legend Biotech’s Carvykti Files for European Approval as Second-Line MM Treatment
•
GenScipt Biotech Corp. (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), through its subsidiary Legend Biotech Corporation (NASDAQ: LEGN), has announced a market approval filing in Europe for its chimeric antigen receptor (CAR)-T therapy Carvykti (ciltacabtagene autoleucel). The therapy is proposed as a second-line treatment for recurrent/refractory (R/R)…
-
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
•
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced that the closing conditions for a licensing agreement between its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), and the Swiss pharmaceutical giant Novartis AG (NYSE: NVS) have been met. The agreement, initially revealed in November 2023,…
-
GenScipt Biotech Corp. Expands Oligonucleotide and Peptide Manufacturing in Zhenjiang
•
China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the expansion of its manufacturing facility for oligonucleotide and peptide products at Zhenjiang, Jiangsu province. This strategic move aims to enhance the company’s production capabilities to meet the growing demand for these specialized products. Enhanced Oligonucleotide…
